SuperGen Plans Dacogen Bone Marrow Disorder NDA; Pharmion Files Vidaza
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The "state of the art" clinical trials in SuperGen’s Dacogen NDA for myelodysplastic syndrome may give the product an edge over Pharmion’s pending MDS agent, Vidaza, SuperGen claims.
You may also be interested in...
SuperGen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal
SuperGen may develop Orathecin as combo therapy following NDA withdrawal. Firm withdrew application in advance of anticipated negative action from FDA. SuperGen is moving ahead with a combination trial with gemcitabine
SuperGen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal
SuperGen may develop Orathecin as combo therapy following NDA withdrawal. Firm withdrew application in advance of anticipated negative action from FDA. SuperGen is moving ahead with a combination trial with gemcitabine
SuperGen Dacogen rolling NDA
SuperGen plans to complete submission of Dacogen (decitabine) for myelodysplastic syndrome (MDS) "within the third quarter." The rolling submission began with the chemistry, manufacturing & controls section, the firm announced June 1. FDA cleared Pharmion's MDS agent Vidaza (azacitidine) May 19, more than a month ahead of the product's June 29 priority review deadline. SuperGen assured investors in February that Vidaza approval will not block Dacogen from being approved (1Pharmaceutical Approvals Monthly March 1, 2004, p. 5)...